Chugai Pharmaceutical Co., Ltd. (CHGCF)

Market Cap	86.02B
Revenue (ttm)	8.16B
Net Income (ttm)	2.74B
Shares Out	n/a
EPS (ttm)	1.66
PE Ratio	31.41
Forward PE	n/a
Dividend	1.23 (2.25%)
Ex-Dividend Date	Jun 27, 2025

Volume	2,480
Average Volume	3,944
Open	54.68
Previous Close	50.50
Day's Range	49.98 - 54.68
52-Week Range	30.36 - 72.30
Beta	0.76
RSI	50.95
Earnings Date	Apr 24, 2025

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrys...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1925
• Employees: 5,026
• Stock Exchange: OTCMKTS
• Ticker Symbol: CHGCF

Financial Performance

In 2024, Chugai Pharmaceutical's revenue was 1.17 trillion, an increase of 5.33% compared to the previous year's 1.11 trillion. Earnings were 387.32 billion, an increase of 19.00%.

Financial numbers in JPY